In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

This column, forecasting a Trump election win, last week expressed surprise so many news consumers remain loyal to media ...

The 868-page report of the official inquiry into Australia’s Covid-19 response, like the inquiry itself, is not fit for ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 billion. However many analysts felt the company had paid far too much ...

A pioneering DNA test is being rolled out on the NHS as experts say there is a one in four chance of another pandemic on the scale of Covid-19 in the next decade ...

This strategic move positions BioVaxys alongside major players like AstraZeneca and Genentech, enhancing its role in developing priority vaccine programs. For further insights into TSE:BIOV stock, ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP). The drugmaker said ...

Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...